OncoMatch/Clinical Trials/NCT03510208
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Is NCT03510208 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Panitumumab and Panitumumab-IRDye800 for malignant brain neoplasm.
Treatment: Panitumumab · Panitumumab-IRDye800 · POINPOINT-IR9000 — The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: investigational drug
Received an investigational drug within 30 days prior to first dose of Panitumumab-IRDye800.
Lab requirements
Blood counts
Platelet count < 75,000/mm3
Kidney function
Serum creatinine > 1.5 times upper limit of normal
Liver function
significant liver disease as determined by PI
Cardiac function
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); unstable angina within 6 months prior to enrollment; evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in males or greater than 460 ms in females)
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease as determined by PI; or unstable angina within 6 months prior to enrollment. Platelet count < 75,000/mm3. Serum creatinine > 1.5 times upper limit of normal. Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in males or greater than 460 ms in females).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University School of Medicine · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify